THE TRUTH ABOUT: Biopath holdings - The Untold Story

Is This Penny Stock a Buy After a 180% Rally?

Bio-Path Holdings surged 180% on promising obesity drug results. Discover why this penny stock's pivot from cancer treatments and Nasdaq delisting challenges could matter for investors.

Barchart · Dec 29, 2024

A Preview Of Bio-Path Holdings's Earnings

Bio-Path Holdings (NASDAQ:BPTH) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Bio-Path Holdings will report an earnings per share (EPS) of $-0.45.

Benzinga · May 16, 2022

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Benzinga · Apr 13, 2022